Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H19N3O5S |
| Molecular Weight | 389.426 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C3=CC=CC(OS(O)(=O)=O)=C13)C(=O)C(CN4C=CN=C4C)CC2
InChI
InChIKey=FKMUSAHZDJNPJY-UHFFFAOYSA-N
InChI=1S/C18H19N3O5S/c1-11-19-8-9-21(11)10-12-6-7-14-16(18(12)22)13-4-3-5-15(17(13)20(14)2)26-27(23,24)25/h3-5,8-9,12H,6-7,10H2,1-2H3,(H,23,24,25)
| Molecular Formula | C18H19N3O5S |
| Molecular Weight | 389.426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Ondansetron 8-sulfate is a metabolite of the ondansetron, a drug which is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery. Ondansetron is extensively metabolized in humans; the primary metabolic pathway is hydroxylation on the indole ring followed by glucuronide or sulfate conjugation.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:50:48 UTC 2023
by
admin
on
Sat Dec 16 10:50:48 UTC 2023
|
| Record UNII |
59D7QNM478
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
59D7QNM478
Created by
admin on Sat Dec 16 10:50:48 UTC 2023 , Edited by admin on Sat Dec 16 10:50:48 UTC 2023
|
PRIMARY | |||
|
15700432
Created by
admin on Sat Dec 16 10:50:48 UTC 2023 , Edited by admin on Sat Dec 16 10:50:48 UTC 2023
|
PRIMARY | |||
|
126671-73-6
Created by
admin on Sat Dec 16 10:50:48 UTC 2023 , Edited by admin on Sat Dec 16 10:50:48 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
